Total Payments
$6,697
2024 Payments
$665.83
Companies
40
Transactions
364
Medicare Patients
3,443
Medicare Billing
$513,971
Payment Breakdown by Category
Food & Beverage$6,697 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,697 | 364 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $910.27 | 31 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $839.41 | 61 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $805.49 | 37 | $0 (2022) |
| Merck Sharp & Dohme LLC | $665.66 | 35 | $0 (2024) |
| ABBVIE INC. | $486.53 | 32 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $444.24 | 21 | $0 (2024) |
| Lilly USA, LLC | $216.54 | 14 | $0 (2024) |
| Amgen Inc. | $206.43 | 15 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $193.99 | 14 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $179.78 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $665.83 | 24 | AstraZeneca Pharmaceuticals LP ($213.52) |
| 2023 | $1,268 | 50 | AstraZeneca Pharmaceuticals LP ($307.58) |
| 2022 | $793.41 | 51 | Merck Sharp & Dohme LLC ($160.96) |
| 2021 | $985.29 | 56 | AstraZeneca Pharmaceuticals LP ($293.07) |
| 2020 | $525.58 | 30 | Boston Scientific Corporation ($117.77) |
| 2019 | $503.49 | 36 | Janssen Pharmaceuticals, Inc ($109.93) |
| 2018 | $742.32 | 42 | Novartis Pharmaceuticals Corporation ($352.02) |
| 2017 | $1,213 | 75 | Janssen Pharmaceuticals, Inc ($332.63) |
All Payment Transactions
364 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: Gastroenterology | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/29/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: Biological | ||||||
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/20/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: NEUROSCIENCE | ||||||
| 09/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: DIABETES | ||||||
| 08/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: Cardio-renal | ||||||
| 07/08/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: NEUROSCIENCE | ||||||
| 07/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), TRULANCE | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Gastroenterology | ||||||
| 06/18/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $28.21 | General |
| 06/08/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $15.12 | General |
| Category: Biological | ||||||
| 05/23/2024 | COLOPLAST CORP | Titan (Device) | Food and Beverage | In-kind items and services | $133.02 | General |
| Category: Men's Health | ||||||
| 05/20/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/13/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: NEPHROLOGY | ||||||
| 04/26/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.83 | General |
| Category: NEUROSCIENCE | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Respiratory | ||||||
| 04/02/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug), BREZTRI, FARXIGA | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Respiratory | ||||||
| 02/28/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.08 | General |
| Category: Cardiovascular | ||||||
| 02/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: Diabetes | ||||||
| 02/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: DIABETES | ||||||
| 01/26/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: Diabetes | ||||||
| 12/08/2023 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $9.88 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 765 | 1,624 | $244,293 | $117,275 |
| 2022 | 15 | 810 | 1,538 | $237,792 | $116,117 |
| 2021 | 15 | 783 | 1,768 | $246,455 | $123,578 |
| 2020 | 19 | 1,085 | 2,179 | $332,750 | $157,002 |
Total Patients
3,443
Total Services
7,109
Medicare Billing
$513,971
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 381 | $60,960 | $30,001 | 49.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 154 | 443 | $53,160 | $26,868 | 50.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 185 | 201 | $59,898 | $26,469 | 44.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 129 | 147 | $26,460 | $12,758 | 48.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 67 | $10,251 | $6,047 | 59.0% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 35 | 172 | $9,632 | $4,849 | 50.3% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 11 | 108 | $7,560 | $4,625 | 61.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 12 | 14 | $10,850 | $2,923 | 26.9% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 14 | 30 | $3,030 | $1,478 | 48.8% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 17 | 24 | $1,752 | $903.67 | 51.6% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 26 | 37 | $740.00 | $352.24 | 47.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 175 | 197 | $58,706 | $29,878 | 50.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 144 | 352 | $56,320 | $28,041 | 49.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 126 | 375 | $45,000 | $20,690 | 46.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 117 | 132 | $23,760 | $10,678 | 44.9% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 27 | 106 | $10,706 | $5,339 | 49.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 53 | $8,109 | $4,195 | 51.7% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2022 | 39 | 150 | $8,400 | $3,809 | 45.3% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 24 | 25 | $7,500 | $3,345 | 44.6% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Office | 2022 | 26 | 28 | $6,860 | $3,288 | 47.9% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 12 | 13 | $2,860 | $2,039 | 71.3% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Office | 2022 | 16 | 25 | $3,325 | $1,669 | 50.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $2,626 | $1,264 | 48.1% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 15 | 16 | $1,712 | $880.88 | 51.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 14 | 16 | $1,168 | $645.98 | 55.3% |
About Dr. Irina Chteingardt, MD
Dr. Irina Chteingardt, MD is a Internal Medicine healthcare provider based in Mayfield Hts, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376563734.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Irina Chteingardt, MD has received a total of $6,697 in payments from pharmaceutical and medical device companies, with $665.83 received in 2024. These payments were reported across 364 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($6,697).
As a Medicare-enrolled provider, Chteingardt has provided services to 3,443 Medicare beneficiaries, totaling 7,109 services with total Medicare billing of $513,971. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Mayfield Hts, OH
- Active Since 07/20/2006
- Last Updated 03/13/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1376563734
Products in Payments
- ENTRESTO (Drug) $805.66
- XARELTO (Drug) $720.26
- ELIQUIS (Drug) $444.24
- VERQUVO (Drug) $441.26
- FARXIGA (Drug) $336.94
- LOKELMA (Drug) $282.44
- QULIPTA (Drug) $184.59
- JYNARQUE (Drug) $179.78
- BREZTRI (Drug) $166.76
- Aimovig (Biological) $153.16
- MOUNJARO (Drug) $151.52
- BELSOMRA (Drug) $144.48
- WATCHMAN (Device) $136.00
- Titan (Device) $133.02
- VRAYLAR (Drug) $132.60
- Vascepa (Drug) $114.11
- LINZESS (Drug) $111.93
- UBRELVY (Drug) $97.70
- LONHALA MAGNAIR (Drug) $95.06
- BRILINTA (Drug) $84.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Mayfield Hts
Gregg Faiman, Md, MD
Internal Medicine — Payments: $372,765
Internal Medicine $372,765
Donald Ebersbacher, Md, MD
Internal Medicine — Payments: $9,653
Internal Medicine $9,653
Claudia Villabona, Md, MD
Internal Medicine — Payments: $5,522
Internal Medicine $5,522
Dr. Anna Egriselashvili, Md, MD
Internal Medicine — Payments: $5,363
Internal Medicine $5,363
Dr. Felix Vilinsky, M.d, M.D
Internal Medicine — Payments: $4,788
Internal Medicine $4,788
Erik Ostler, M.d, M.D
Internal Medicine — Payments: $4,197
Internal Medicine $4,197